Drug Approval | April 23, 2025
A new weapon in the global fight against malaria
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing
Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Subscribe To Our Newsletter & Stay Updated
